Gilead Sciences Inc (GILD)
Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
News
Kite and Arcellx Forge Powerful Alliance to Revolutionize Multiple Myeloma Treatment
Gilead Sciences Inc*s EPS Surges by 3900% in Q1 2023, Despite Revenue Decline
contribution in profit margins at the company all along the financial time-frame closing Dec 31 2022
revenue receded in single digits, at GILD amid the financial span closing Sep 30 2022
The company announced that Revenues went up modest, over the most recent fiscal period